RecruitingPhase 4NCT03063892

Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

Evaluating the Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion in Hip Fracture Patients


Sponsor

Gregory M Georgiadis MD

Enrollment

200 participants

Start Date

Aug 30, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.


Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Saline solution and a drug called Tranexamic Acid (TXA) for people with hip fractures. The study is currently recruiting participants at 1 location. People eligible for this study include aged 60 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTranexamic Acid (TXA)

Tranexamic acid is an antifibrinolytic used to control bleeding

DRUGSaline solution

Saline solution is used as the placebo comparator


Locations(1)

ProMedica Toledo Hospital

Toledo, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03063892


Related Trials